Lansdowne Partners UK LLP Takes Position in PureTech Health PLC Sponsored ADR $PRTC

Lansdowne Partners UK LLP acquired a new stake in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 14,106,660 shares of the company’s stock, valued at approximately $260,973,000. PureTech Health comprises 17.1% of Lansdowne Partners UK LLP’s investment portfolio, making the stock its 2nd largest holding. Lansdowne Partners UK LLP owned 58.37% of PureTech Health at the end of the most recent reporting period.

Separately, Diadema Partners LP acquired a new position in PureTech Health during the second quarter worth $126,000. 0.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d)” rating on shares of PureTech Health in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, PureTech Health currently has a consensus rating of “Sell”.

PureTech Health Price Performance

NASDAQ:PRTC opened at $16.55 on Tuesday. The company’s 50 day moving average is $17.93 and its 200-day moving average is $17.33. PureTech Health PLC Sponsored ADR has a 12 month low of $13.30 and a 12 month high of $20.00.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.